The other clinical features of WM occur secondary to the production of high levels of monoclonal IgM protein by the malignant lymphoplasmacytes.
- IgM, as a high molecular-weight protein, increases blood viscosity.
- The increased viscosity results in a reduced flow rate, according to Poiseuille's law.
- Reduced blood flow contributes to damage in multiple sites. Microvascular structures, such as those of the eye, kidneys and neurons, are particularly sensitive to this effect.
- As a result, the classic (albeit rare) 'hyperviscosity syndrome' associated with WM is characterised by blurred vision, bleeding diathesis and peripheral neuropathy.
- IgM may act directly as an autoantibody to red blood cells, resulting in a Coombs-positive autoimmune haemolytic anaemia.
- Amorphous parts of IgM molecules may deposit in the glomerulus and lead to the activation of complement and subsequent immune-mediated nephropathy.
- 40 per cent of patients with recently-diagnosed Waldenstrom's macroglobulinaemia have a detectable anaemia on a complete blood examination.
- Additionally, lymphocytosis and monocytosis are commonly seen.
- Thrombocytopaenia may occur due to infiltration of the bone marrow by lymphoplasmacytic cells, but the platelet count rarely falls below 50,000µL.
- Generally only necessary in patients with clinical evidence of bleeding.
- The most common abnormality seen in this investigation is the prolongation of the prothrombin time, which is due to IgM paraprotein interfering with the polymerisation of fibrin.
- Prolongation of the bleeding time may be seen, due to interactions between the IgM paraprotein and surface glycoprotein receptors on platelets.
- IgM, as a high molecular-weight protein, contributes to an increase in plasma viscosity.
- Normal plasma viscosity is usually 1.5 centipoise (CP), but symptoms of hyperviscosity are not often seen below 4 CP.
Serum protein electrophoresis
- One pathologically necessary component to diagnose WM is the presence of large levels of monoclonal IgM proteins in the peripheral blood. This is detected using serum protein electrophoresis.
- The SPEP should reveal a dense band of monoclonal IgM protein; the so-called spike'.
Bone marrow biopsy
- Bone marrow biopsy should reveal infiltration of the marrow by lymphoplasmacytic cells with a characteristic immunophenotype. Although the exact list of surface biomarkers of these characteristic cells is extensive, they are unlikely to be tested in medical student final exams.
Although all of these investigations may provide useful information, the SPEP and bone marrow biopsy are the only two that are technically necessary for meeting the diagnostic criteria for WM.
- IgM monoclonal gammopathy of any size, as determined by serum protein electrophoresis
- Infiltration of >10% of the bone marrow by cells with a typical immunophenotype:
- Surface IgM+
Although not strictly part of diagnostic criteria per se, common clinical features of WM include:
- Fatigue (according to BMJ Best Practice, up to 66% of patients with WM present with fatigue).
- Anorexia. Despite being nonspecific, this is thought to be the second most common symptom in WM.
- Peripheral neuropathy.
It should be noted that there are different international scoring systems used to define the diagnostic criteria of WM. The differences between them are quite minor, in that some of them (Mayo Clinic) specify that there needs to be >10% infiltration of the bone marrow, while others (World Consensus Panel, World Health Organisation) only require that the lymphoplasmacytic cells infiltrate the bone marrow at all. However, this is unlikely to be tested in medical student finals and so is included here for the sake of correctness only.
Monoclonal gammopathy of undetermined significance (MGUS)
- MGUS and WM exist on the same pathologic spectrum of increased plasma levels of immunoglobulins.
- The serum m-protein is not as high in MGUS as it is in WM, and does not present with the same symptoms of hyperviscosity as WM.
- MGUS is usually clinically asymptomatic, and a raised serum m-protein is often only detected incidentally.
- The bone marrow biopsy of a patient with MGUS will show less invasion (usually <10%) by lymphoplasmacytic cells than in WM.
Multiple myeloma (MM)
- Fatigue occurs commonly in both MM and WM.
- Anaemia can be seen in both diseases.
- Both diseases are typically characterised by high levels of monoclonal protein, though multiple myeloma with raised IgM is very rare.
- Neurologic symptoms can develop in both diseases, albeit due to different mechanisms. The hyperviscosity of WM may cause paresthesias and radiculopathy. Bone fragments due to fractured vertebral bodies can cause spinal cord compression in MM.
- WM does not usually present with bony lesions, and MM is not commonly associated with symptoms of hyperviscosity.
- Hepatosplenomegaly is not a common feature of MM, whereas it does frequently occur in WM. The bone marrow biopsy in a patient with MM will show the infiltration of cells that are phenotypically distinct from those in a patient with WM.
Chronic lymphocytic leukaemia
- Both may present with fatigue and hepatomegaly.
- Immunohistochemistry and flow cytometry will reveal cells that are specific for each type of malignancy. For CLL, these will be CD5+, CD19+ CD23+ cells. In contrast, cells in WM will be CD5± and CD23-.
Since there is little high-quality evidence regarding the long-term survival benefits of particular chemotherapeutic drugs, best practice in managing WM is commonly based on expert opinion. There are several ongoing clinical trials focusing on different regimens. Additionally, young patients with aggressive disease may opt to join clinical trials featuring autologous stem cell transplant, which will affect selection of chemotherapeutic agents so as to avoid damaging stem cells.
Patients with WM/MGUS can be grouped into different categories depending on two main factors: whether or not they are symptomatic, and whether or not symptomatic patients have evidence of hyperviscosity.
- Asymptomatic patients with WM or MGUS are not recommended to have active treatment due to the potential harms of chemotherapy.
- According to UpToDate, it is recommended to monitor asymptomatic patients who have been diagnosed with WM, through Complete Blood Exams and SPEP studies every four to five months for the first five years following diagnosis and annually thereafter.
- Patients with symptoms of hyperviscosity (headaches, blurred vision, oronasal bleeding) require emergency plasmapheresis.
- Of the patients that are symptomatic but without clinical evidence of hyperviscosity, UpToDate recommends a clinical assessment of the symptom burden.
- In patients with a low symptom burden, single-agent Rituximab is recommended as it is likely to be better tolerated than a combined regimen.
- In patients with higher symptom burden, combined chemotherapy with Rituximab and Bendamustine is recommended.
- As many as 30 per cent of patients with WM complain of symptoms related to hyperviscosity. This may include: dizziness, blurred vision, headache, dizziness and in extreme cases even disturbed consciousness and coma.
- This is a syndrome secondary to chronic hyperviscosity. Due to increased vascular permeability, there is malignant infiltration of the perineurium, resulting in a variety of neurological symptoms (in addition to the microvascular complications of hyperviscosity initially).
Transformation to high-grade non-Hodgkin's lymphoma (Richter transformation)
- Since WM is a low-grade B cell lymphoma, it may undergo transformation to high-grade lymphomas such as Diffuse Large B Cell Lymphoma (DLBCL). This transformation is rare, however.